No Data
No Data
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Insiders, Who Hold 28% of the Firm Would Be Disappointed by the Recent Pullback
Jiangsu Aidea Pharmaceutical (688488.SH): The actual controller and president cumulatively increased their shareholding by 0.11%.
Jiangsu Aidea Pharmaceutical (688488.SH) announced that on July 10, 2024, the actual controller and president cumulatively increased their holdings of the company's shares by 446,013 shares, accounting for 0.11% of the total share capital of the company, through the Shanghai Stock Exchange trading system in a centralized bidding manner, with a total investment of RMB 4.2352 million, which has exceeded half of the minimum amount of this shareholding plan. The main body of the shareholding will continue to increase the company's shares according to the relevant shareholding plan within the implementation period of the shareholding plan.
Jiangsu Aidea Pharmaceutical (688488.SH) has currently no relevant cooperation with Gilead.
Jiangsu Aidea Pharmaceutical (688488.SH) stated on the interactive platform on June 27th that the company currently has no related cooperation with Gilead.
Here's Why Jiangsu Aidea Pharmaceutical (SHSE:688488) Can Afford Some Debt
Jiangsu Aidea Pharmaceutical (688488.SH): Approval notice for the listing application of Active Pharmaceutical Ingredient Enavuirin received.
On June 3rd, Gelunhui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that its wholly-owned subsidiary, Yangzhou Aidi Pharmaceutical Technology Co., Ltd. (collectively referred to as 'Aideo Pharmaceutical' or 'the Company'), received the 'Approval Notice for the Listing Application of Chemical Raw Materials for Enoxavir' (Notice No.: 2024YS00494) issued by the State Drug Administration. The chemical raw material Enoxavir of the company has obtained the 'Approval Notice for the Listing Application of Chemical Raw Materials', indicating that the raw material has met the relevant drug evaluation technical standards of the country, and has been approved for use in domestic formulations, and can be subsequently applied to the production of Enoxavir tablets and Ennomitin tablets.
Eddy Pharmaceuticals (688488.SH) reported first-quarter results with a net loss of 13.6069 million yuan
Eddy Pharmaceuticals (688488.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
No Data